Cancer Research Audrey Hepburn EMT and Cancer Progression and Treatment
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
[Cancer Research 59, 367-371, January 1, 1999]
© 1999 American Association for Cancer Research
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Galffy, G.
Right arrow Articles by Antony, V. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Galffy, G.
Right arrow Articles by Antony, V. B.
[Cancer Research 59, 367-371, January 15, 1999]
© 1999 American Association for Cancer Research

Carcinogenesis

Interleukin 8

An Autocrine Growth Factor for Malignant Mesothelioma

Gabriella Galffy, Kamal A. Mohammed, Patrick A. Dowling, Najmunnisa Nasreen, Melissa J. Ward and Veena B. Antony1

Division of Pulmonary and Critical Care Medicine, Department of Medicine, Veterans’ Affairs Medical Center, Indiana University School of Medicine, Indianapolis, Indiana 46202


   ABSTRACT
Top
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Interleukin 8 (IL-8) is a potent chemokine that also has a direct growth-potentiating effect on certain tumors. In the present study, we determined IL-8 levels in human malignant mesothelioma (MM) effusions and congestive heart failure pleural fluids. We also investigated antigenic IL-8 production by different MM cell lines, and we describe the role of IL-8 in the autocrine growth regulation of MMs. Mesothelial (CRL-9444 = MC) and MM (CRL-2081 = MM-1, CRL-5915 = MM-2, and CRL-5820 = MM-3) cell lines were grown using standard culture methods. The bioactive IL-8 levels were measured in supernatants of cultured cells by ELISA, and the expression of cell-associated immunoreactive IL-8 was observed by immunohistochemistry. The proliferative activity was determined by thymidine ([3H]thymidine) incorporation and also by direct cell counts after incubation with varying concentrations of IL-8 in the presence/absence of specific polyclonal IL-8 antibody. We found significantly higher levels of IL-8 in mesothelioma pleural fluids than congestive heart failure and a time-dependent increase in IL-8 levels in MM-1 and MM-2 cell supernatants during 96 h of incubation. IL-8 levels were nearly undetectable in MM-3 and MC cell line supernatants. In MM-1 and MM-2 cells, IL-8 caused a dose-dependent increase of [3H]thymidine incorporation to maximal levels of 46.3 ± 3.6% and 12.3 ± 1.6% (P < 0.001), respectively, when compared with serum-free medium as control. Neutralization of IL-8 significantly decreased proliferative activity of MM-1 and MM-2. IL-8 did not induce proliferative activity in MM-3 and MC cells. We conclude that IL-8 had a direct growth-potentiating activity in MMs.


   INTRODUCTION
Top
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
MM,2 unlike other pulmonary tumors, is characterized by local tumor extension and invasion of surrounding tissue without distant metastasis. It is a relatively rare tumor, but its incidence appears to be increasing. The present annual incidence of MMs is ~11.4 per one million in men and 2.8 per one million in women in the United States (1) . Despite attempts to advance early diagnosis and use combination therapies, the prognosis of the patients with MM is poor. The average survival time is about 7–9 months after diagnosis (1 , 2) . Unfortunately, there is no effective treatment for prolonging survival at this time.

Several tumors produce specific autocrine growth factors that improve their growth capacity and ability for metastasis (3, 4, 5) . IL-8, a member of the super gene family of C-X-C chemokines, is chemotactic for and activates neutrophils (6, 7, 8, 9) . By increasing expansion of adhesion molecules (10) , it also facilitates leukocyte-endothelial and leukocyte-mesothelial interactions, which are involved in the inflammatory invasion of neutrophils. IL-8 has been described as an important angiogenic factor for the development of new capillaries in vivo (11, 12, 13) . In empyema, IL-8 levels were reported to be severalfold higher than mesothelioma and were comparable in parapneumonic effusion; however, in tuberculosis, the IL-8 levels were very low (14) . Several immune and nonimmune cells, including endothelial and mesothelial cells, have been found to produce IL-8 (15 , 16) . In addition, IL-8 has also been shown to be generated by a variety of tumors such as melanoma (3) and bronchogenic carcinoma (17) . It serves as an autocrine growth factor, in the case of melanoma, allowing for local tumor growth and invasion (18 , 19) .

The aim of the present study was to determine differences in IL-8 levels from human MM effusions and CHF pleural fluids as control. It was also designed to investigate the autocrine IL-8 production by different mesothelioma and mesothelial cells and describes the potential role of IL-8 in the autocrine growth regulation of mesothelioma and mesothelial cells. We found elevated levels of IL-8 in human mesothelioma pleural fluids compared with CHF. In vitro, mesothelioma cells, but not mesothelial cells, produced high levels of IL-8. We verified that IL-8 is a direct growth-potentiating factor for mesothelioma but not for mesothelial cells.


   MATERIALS AND METHODS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Reagents.
Recombinant human IL-8, monoclonal anti-IL-8 Ab (mouse IgG1; this Ab does not cross-react with other C-X-C chemokines), mouse IgG-isotype and specific polyclonal goat anti-IL-8 Ab (polyclonal IL-8 Ab; this Ab does not cross-react with MGSA, neutrophil activating protein-2, or any other chemokine) were purchased from R & D Systems (Minneapolis, MN). Purified nonspecific goat IgG was purchased from Sigma Chemical Co. (St. Louis, MO). [3H]Thymidine was obtained from Amersham Life Science (Arlington Heights, IL).

Human Pleural Mesothelial and MM Cell Lines.
One mesothelial cell line (CRL-9444) and three mesothelioma cell lines (CRL-2081, CRL-5915, and CRL-5820) were purchased from American Type Culture Collection (Rockville, MD). The mesothelial cells were resuspended in Ham’s 199 culture medium (Life Technologies, Inc., Grand Island, NY) containing 10% fetal bovine serum (Harlan Bioproducts, Indianapolis, IN), penicillin (100 units/ml), and streptomycin (100 g/ml). Mesothelioma cells were cultured in RPMI 1640 culture medium with 10% fetal bovine serum, 100 units/ml penicillin, and 100 µg/ml streptomycin. The cells were plated in 75-cm2 tissue culture flasks (Corning Costar Corp., Cambridge, MA) and incubated at 37°C in 5% CO2 and 95% air. The monolayer was confluent between 8 and 10 days. Mesothelial cells had a classic cobblestone morphology (20) , absence of factor VIII antigen, and presence of cytokeratin (21) . All cells were used between the third and seventh passages.

Human Pleural Fluid.
Twelve patients with pleural effusions secondary to mesothelioma (n = 6) and CHF (n = 6) were studied. Pleural fluids were obtained after informed consent during diagnostic thoracocentesis, as described previously (16 , 22) . In all MM patients, the effusions were exudates with culture negative for infective organisms. A malignant effusion secondary to mesothelioma was defined by at least one of the following criteria: malignant mesothelioma cells in the pleural fluid on cytological examination, or mesothelioma on closed pleural biopsy. Biopsy tissue was examined by microscopy and a special panel of stains to diagnose MM. Three patients had a mixed-type mesothelioma: one was an epithelial type mesothelioma, and two were sarcomatous in nature. Transudative pleural effusions from symptomatic patients with a diagnosis of CHF served as control. The fluids were saved at -70°C for IL-8 ELISA.

Cell Culture Supernatants for IL-8 Determination.
To determine the constitutive production of IL-8 without stimulation, CRL-2081, CRL-5915, CRL-5820 mesothelioma, and CRL-9444 mesothelial cells were plated in 75-cm2 tissue culture flasks (1 x 106 cells/flask), grown to confluence, washed, and replaced with serum-free RPMI 1640 (8 ml/flask) for mesothelioma cells and Ham’s 199 for mesothelial cells. Conditioned media were collected at 24, 48, 72, and 96 h, centrifuged at 900 x g for 10 min, and saved at -70°C for IL-8 analysis by ELISA.

IL-8 ELISA.
Extracellular immunoreactive IL-8 levels were measured by "sandwich" enzyme immunoassay (R&D System, Minneapolis, MN) as described previously (16) . The samples were added to 96-well microtiter plates, which were coated with murine monoclonal Ab to IL-8. The unbound protein was washed three times, and an enzyme-linked polyclonal antibody specific to IL-8 was added. The plates were again washed three times, and substrate solution was added to the wells. After 30 min of incubation, stop solution was added to each well. The amount of IL-8 was determined by absorbance of the samples by comparing the standards at 450 nm using the ELISA reader.

Immunohistochemistry for IL-8.
Unstimulated mesothelial and mesothelioma cells were immunostained with avidin-biotin conjugate and peroxidase as described previously (7) . The cells were cultured in Lab-Tek chamber slides (Nunc, Naperville, IL). The confluent cultures were fixed in absolute methanol, and endogenous peroxidase activity was quenched with 1% hydrogen peroxide. Nonspecific binding sites were blocked with 1% normal horse serum for 50 min, permeabilized in 0.1% Triton X-100 for 10 min, and overlaid with 1:1000 dilution of mouse monoclonal anti-human IL-8 Ab for 30 min. The negative controls were overlaid with mouse IgG isotype. The slides were rinsed with PBS and overlaid with avidin-biotin conjugated goat anti-mouse IgG (Vectastain ABC kit; Vector Laboratories, Burlingame, CA) for 60 min. The slides were washed and incubated for 5 min in peroxidase substrate solution (3,3'-diaminobenzidine) washed in PBS and counterstained by Mayer’s hematoxylin (Sigma Chemical Co.). The cells were dehydrated in graded alcohol and xylene and covered with glass.

Proliferative Activity.
Mesothelial and mesothelioma cell line proliferation was determined by a [3H]thymidine uptake assay as described by Lauber et al. (23) and Hott et al. (24) . Cells (2 x 104) were plated in 48-well plates and grown to confluence. Then the medium was replaced by RPMI 1640 or Ham’s 199 and incubated overnight. Various concentrations of IL-8 (5, 25, 50, and 100 ng/ml), polyclonal goat anti-human IL-8 specific Ab (1, 5, 10 and 20 µg/ml), or nonspecific purified goat IgG (1, 5, 10, and 20 µg/ml) as control were added. After 24-h incubation at 37°C in 5% CO2 95% air, 0.5 µCi of [3H]thymidine was added to each well, and the plates were reincubated for 24 h. The cells were washed three times in complete HBSS and harvested from the plates with 0.5% EDTA, precipitated in 5% trichloroacetic acid, and centrifuged at 3000 rpm for 10 min. They were resuspended in 0.1 N NaOH, placed in scintillation fluid, and counted in a ß-scintillation counter. All experiments were done in triplicate, and data are expressed as percentage of stimulation (cpm produced by the test factors/cpm produced by SFMx 100). In addition, mesothelial and mesothelioma cell proliferation was measured by direct cell counts (hemocytometer). After 48 h of seeding, the cell culture medium was changed to SFM plus either 50 ng/ml IL-8 or 10 µg/ml anti-IL-8 Ab or SFM alone. Cell counts were obtained after 48 h of incubation. The selected IL-8 concentrations had no effect on the mesothelial and mesothelioma cell viability as demonstrated by trypan blue exclusion.

Statistical Analysis.
All values are expressed as mean ± SD. Data were compared using Student’s t test and ANOVA. Values were considered to be statistically significant when P was <0.05.


   RESULTS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
Antigenic IL-8 Levels in Human Pleural Fluids.
Twelve patients with pleural effusions were studied. Six had pleural effusions secondary to mesothelioma (three mixed, one epithelial, and two sarcomatous). A control group of six patients had CHF with bilateral transudative effusions. IL-8 levels (Fig. 1)Citation were significantly (P < 0.001) elevated in patients with MM (8.78 ± 3.59 ng/ml) compared with patients with CHF (0.07 ± 0.05 ng/ml).



View larger version (8K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 1. IL-8 levels in human pleural fluids. The results represent triplicate determination (ng/ml; data are presented as means; bars, SD) from n number of patients studied. IL-8 levels were significantly (**, P < 0.001) higher in mesothelioma pleural fluids (n = 6) as compared with CHF pleural fluids (n = 6).

 
Detection of IL-8 in Human Mesothelioma and Mesothelial Cell Culture Supernatants.
All three mesothelioma cell lines, tested by ELISA, produced detectable levels of human IL-8 without stimulation (Fig. 2)Citation . However, IL-8 was not detected in supernatants from mesothelial cells, even after 96 h of incubation. We observed a significant, time-dependent increase in IL-8 levels in all three mesothelioma supernatants. After 96 h of incubation, IL-8 levels ranged between 36.2 ± 6.3 pg/ml in the CRL-5820 and 2689.4 ± 60.2 pg/ml in the CRL-2081 cell line. In the CRL-5915 mesothelioma cell line, the IL-8 concentration was 516.4 ± 19.0 pg/ml at the end of the incubation period. In the CRL-5820 cell line, the IL-8 levels were insignificant throughout the experiment and are close to the minimum detectable sensitivity of the test (31.2 pg/ml).



View larger version (12K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 2. Detection of antigenic IL-8 protein in mesothelioma and mesothelial cell line supernatants by ELISA. The values represent means of duplicate determination from six independent experiments, in pg/ml; bars, SD. IL-8 levels at 48, 72, and 96 h in the CRL-2081 and CRL-5915 mesothelioma cell line supernatants were significantly (P < 0.001) greater than CRL-5820 mesothelioma and the mesothelial cell lines. The values were statistically insignificant in CRL-5820.

 
We also used immunohistological localization to demonstrate the cellular antigenic IL-8 in mesothelioma and mesothelial cells. Expression of immunoreactive cell-associated IL-8 by all three mesothelioma cell lines can be seen in Fig. 3Citation , whereas the mesothelial cell line has no detectable IL-8 production.



View larger version (75K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 3. Histochemical immunostaining of IL-8 in mesothelial and mesothelioma cell lines (x100). A, mesothelial cell negative control. In B, the mesothelial cell positive control stained with anti-IL-8 Ab demonstrates an absence of IL-8. C, CRL-2081 negative control. D, CRL-2081 positive control. E, CRL-5915 negative control. F, CRL-5915 positive control. G, CRL-5820 negative control. H, CRL-5820 positive control. Intense IL-8 reactivity is visible in mesothelioma-positive controls.

 
Mesothelioma and Mesothelial Cell Proliferation in Response to IL-8.
To determine the effect of human IL-8 protein in regulating human mesothelioma and mesothelial cell proliferation, various concentrations of IL-8 (5, 25, 50, and 100 ng/ml), with varying concentrations of polyclonal goat anti-IL-8 Ab (1, 5, 10, and 20 µg/ml; data not shown), or nonspecific goat IgG (control) were added to the cell cultures grown in SFM. The optimal proliferation was noticed at 50 ng/ml of IL-8, and the maximum inhibition of proliferation was observed with 10 µg/ml of polyclonal IL-8 Ab; therefore, this concentration was used in neutralization studies.

IL-8 stimulated the proliferation of CRL-2081 and 5915 mesothelioma cell lines in a dose-dependent manner as determined by [3H]thymidine incorporation (Fig. 4)Citation . Maximal [3H]thymidine uptake occurred in response to 50 ng/ml of IL-8 [CRL-2081, 146.3 ± 3.6% and CRL-5915, 112.3 ± 1.6% (P < 0.001), when compared with SFM, as control]. Incubation with 100 ng/ml of IL-8 did not increase the [3H]thymidine incorporation above the level of 50 ng/ml IL-8 effect [CRL-2081, 138.2 ± 2.7% (P < 0.001) and CRL-5915, 105.9 ± 2.3% (P < 0.05), when compared with SFM]. The proliferation behavior of the CRL-5820 mesothelioma and the mesothelial (CRL-9444) cell lines, however, remained unaltered compared with untreated controls.



View larger version (15K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 4. Growth curve of mesothelioma (CRL-2081, CRL-5915, and CRL-5820) and mesothelial (CRL-9444) cell lines in the presence of various concentrations of IL-8. Data are expressed as means as a standardized percentage of stimulation of [3H]thymidine uptake in SFM after 48 h of culture; bars, SD. For each cell line, the experiments were repeated four times, with triplicate samples. IL-8 induced a significant, dose-dependent increase of [3H]thymidine incorporation in CRL-2081 and CRL-5915 mesotheliomas but not in CRL-5820 and the mesothelial cell lines. **, P < 0.001; and *, P < 0.05 when compared with SFM.

 
Furthermore, addition of specific polyclonal IL-8 Ab significantly inhibited the proliferation of CRL-2081 (61.8 ± 6.7; P < 0.001) and CRL-5915 (50.2 ± 1.5; P < 0.001) mesothelioma cell lines when compared with SFM (Fig. 5A)Citation . However, in CRL-5820 mesothelioma and the mesothelial cells, there was no significant difference in [3H]thymidine incorporation with neutralizing IL-8 Ab. Nonspecific goat IgG was not effective (data not shown).%Direct cell count by hemocytometer also demonstrated that IL-8 induced the proliferation, and the addition of IL-8 Ab inhibited cell proliferation in CRL-2081 [152.1 ± 3.0 (P < 0.001) and 77.5 ± 2.0 (P < 0.05)] and 5915 [110.0 ± 2.4 (P < 0.05) and 68.0 ± 2.8 (P < 0.001)] mesothelioma cell lines (Fig. 5B)Citation . There was no significant response to IL-8 as well as IL-8 Ab in the CRL-5820 and mesothelial cell lines.



View larger version (30K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 5. Effect of specific polyclonal anti-human IL-8 antibody on human mesothelioma and mesothelial cells proliferation. A, data are expressed as means as a standardized percentage of stimulation of [3H]thymidine uptake in SFM after 48 h of culture; bars, SD. B, effect of IL-8 expressed as a percentage of stimulation of cell counts when 100% is the cell count in SFM at 48 h of incubation. For each cell line, the experiments were repeated four times, with triplicate samples; bars, SD. Fifty ng/ml of IL-8 were used for proliferation; 10 µg/ml of polyclonal goat anti-human IL-8 Ab was used to neutralize the IL-8. Neutralization of IL-8 significantly decreased the proliferation of CRL-2081 and 5915 mesothelioma cell lines. Proliferation of the CRL-5820 mesothelioma and mesothelial (CRL-9444) cell lines remained unaltered. **, P < 0.001; and *, P < 0.05 when compared with SFM.

 

   DISCUSSION
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
Our results demonstrate that pleural fluids from patients with mesothelioma contained significantly greater IL-8 levels than did pleural fluid from CHF patients. Malignant pleural effusions, other than mesothelioma, also contain immunoreactive IL-8; however, it is present in significantly smaller quantities than we observed in mesothelioma pleural fluids (7) . All three mesothelioma cell lines constitutively expressed IL-8; however, there was no detectable IL-8 in the supernatants from resting mesothelial cells. In the CRL-5820 mesothelioma cell line, the IL-8 levels were low compared with CRL-2081 and CRL-5915 mesothelioma cell lines. In CRL-2081 and CRL-5915, a significant increase in IL-8 production was observed during 96 h of incubation.

We also studied the effect of exogenous IL-8 and the requirement of IL-8 for growth and proliferation in mesothelioma and mesothelial cells as measured by the [3H]thymidine incorporation and direct cell counts. Treatment with exogenous human IL-8 showed a significant, dose-dependent increase in cell proliferation in CRL-2081 mesothelioma in which highest level of autocrine IL-8 production (2.7 ng/ml) was observed. The increase in proliferative activity was low but significant in CRL-5915 mesothelioma cells, where the IL-8 production (0.5 ng/ml) was lower. Neutralization of IL-8 in these cell lines resulted in a decrease in their proliferation. This is supported by the fact that anti-IL-8 Ab was able to decrease proliferation of these cell lines in a significant fashion. Neither [3H]thymidine incorporation nor cell counts changed after either addition of exogenous IL-8 or anti-IL-8 Ab in the CRL-5820 mesothelioma and mesothelial cell line, where the IL-8 production was nearly undetectable or absent. These findings suggest that the lack of IL-8 binding sites on these cells may be responsible for their unresponsiveness to IL-8.

It is well established that tumor cells produce a number of factors that promote tumor growth, tissue invasion, and metastatic spread. Melanoma cells secreted autocrine growth-stimulatory factors, such as MGSA (MGSA/GRO{alpha}) or basic fibroblast growth factor. MGSA was found to have mitogenic activity for the melanoma cell line Hs 294T, which produces this factor (25) . High levels of MGSA secretion was observed in diverse melanoma cell lines; however, it was absent in benign nevus cells (26) . Recently, another member of the C-X-C supergene family, IL-8, was found to be secreted by melanoma cells in an autocrine fashion. IL-8, potentiates proliferation of melanoma cells and plays an important role in the tumorigenesis and growth of malignant melanoma (3 , 18) . This is supported by the fact that antisense oligonucleotides targeted against human IL-8 mRNA inhibited cell proliferation, colony formation in soft agar, and secretion of IL-8 into culture supernatants (18) . In vivo experiments demonstrated that expression of IL-8 correlates with the metastatic capability of 13 human melanoma cell lines, which were injected into BALB/c mice (27) . We demonstrated that mesothelioma cells similar to melanoma cells release biologically active IL-8, which causes proliferation of mesothelioma cells. The higher proliferative capacity of the tumor is directly related to its capacity to secrete more IL-8, and the differential IL-8 response in different mesothelioma cell lines noticed may be related to their aggressive growth.

Recent studies show that IL-8 receptor B (CXCR-2) is present on melanoma cells and plays a role in the cell growth (28) . A specific Ab directed against the NH2 terminus of IL-8 receptor B (28) as well as a novel inhibitor of IL-8 receptor B (25) have been shown to suppress the growth of melanoma cells. Because of high a degree of sequence homology of MGSA and IL-8, both cause receptor signal transduction when binding to the IL-8 receptor B (29) . However, the presence of another, specific MGSA binding site has been theorized. Interestingly, IL-8 as well as MGSA bind with high affinity to the IL-8 receptor B, but the affinity of MGSA to the IL-8 receptor A is weak compared with the high affinity of IL-8 for this receptor. In an acute burn wound, IL-8 receptor B was restricted to the basal proliferating compartment in healing skin wounds, whereas higher concentrations of IL-8 were detected in the outer layers of the epidermis, providing a chemotactic gradient for the migration of keratinocytes (30) . These results also suggest that the presence of IL-8 receptor B is critical for the proliferative effect of IL-8.

IL-8 has been classified primarily by proinflammatory properties (31) , but it has multiple effects. In response to inflammatory stimuli such as lipopolysaccharide, IL-1, and tumor necrosis factor-{alpha}, IL-8 is produced by a wide variety of cell types including monocytes, neutrophils, lymphocytes, and endothelial and mesothelial cells (11 , 16 , 31) . IL-8 activates neutrophils and increases their adhesion to endothelial cells, which leads to directional transendothelial migration (28) . The effects of IL-8 is not confined only to neutrophils, but it has effects on T and B lymphocytes, basophils, and IL-2-activated natural killer cells as well. IL-8 has a strong chemotactic activity on neutrophils. The described complex effects suggest a functional role for IL-8 in the first line of host defense in vivo. In addition, IL-8 induces proliferation and chemotaxis of human umbilical vein endothelial cells (11) in vitro. In the rat sponge implant model (19) and in the corneal micropocket model (11) , IL-8 has been found to be a potent angiogenic factor in a pattern similar to that seen with tumor necrosis factor-{alpha}, fibroblast growth factor, and vascular endothelial growth factor. Tumor growth beyond 1–2 mm3 was dependent on angiogenesis (32) . The dysregulation of the balance between angiogenic and angiostatic factors is one of the mechanisms maintaining tumor growth by neovascularization. IL-8 is expressed in and secreted by a variety of transformed neoplastic cells (3 , 33) . Significantly elevated IL-8 levels were found in human non-small cell lung cancer (adenocarcinoma and squamous cell carcinoma), which were four times greater than normal lung tissue (17) . These observations suggest that the more aggressive course of adenocarcinomas could be related to their capacity to generate IL-8. Inhibition of IL-8, by addition of neutralizing antisera, attenuated both corneal (17) and neoplastic (33) neovascularization. In non-small cell lung cancer, IL-8 did not act as an autocrine growth factor for proliferation; however, treatment with neutralizing antibody to IL-8 resulted in a decline of tumor-associated vascular density, a reduction in primary tumor size, and reduction of the rate of metastasis (33) . This well-described angiogenic effect of IL-8 could also play an important role in the spread and growth of malignant mesotheliomas.

The findings described in this report demonstrate for the first time that IL-8, which is produced by mesothelioma cells, is a important factor in growth regulation in a subgroup of human MMs. Likewise, the progression of MM may correlate with the level of autocrine IL-8 production. However, it remains to be determined whether IL-8 mediates its proliferative effects through IL-8 receptor B or through a related molecule of the same receptor family, as in melanoma cells (25) . The mechanism responsible for these findings needs to be studied further.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 To whom requests for reprints should be addressed, at Veterans’ Affairs Medical Center, 1481 West 10th Street, 111P, Indianapolis, IN 46202. Fax: (317) 554-0262. E-mail: vantony{at}iupui.edu Back

2 The abbreviations used are: MM, malignant mesothelioma; IL, interleukin; CHF, congestive heart failure; Ab, antibody; MGSA, melanoma growth stimulatory activity; SFM, serum-free medium. Back

Received 3/12/98. Accepted 11/ 9/98.


   REFERENCES
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Connelly R. R., Spirtas R., Myers M. H., Percy C. L., Fraumeni J. F., Jr. Demographic patterns for mesothelioma in the United States. J. Natl. Cancer Inst., 78: 1053-1060, 1987.
  2. Branscheid D., Krysa S., Bauer E., Bulzebruck H., Schirren J. Diagnostic and therapeutic strategy in malignant pleural mesothelioma. Eur. J. Cardio-Thorac. Surg., 5: 466-472, 1991.[Abstract]
  3. Forster E., Kirnbauer R., Urbanski A., Kock A., Luger T. A., Schwarz T. Human melanoma cells produce interleukin-8, which function as an autocrine growth factor. Arch. Dermatol. Res., 283: 26 1991.
  4. Relf M., LeJeune S., Scott P. A., Fox S., Smith K., Leek R., Moghaddam A., Whitehouse R., Bicknell R., Harris A. L. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor ß-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res., 57: 963-969, 1997.[Abstract/Free Full Text]
  5. Halaban R., Kwon B. S., Ghosh S., Delli Bovi P., Baird A. bFGF as an autocrine growth factor for human melanomas. Oncogene Res., 3: 177-186, 1988.[Medline]
  6. Nanney L. B., Mueller S. G., Bueno R., Peiper S. C., Richmond A. Distributions of melanoma growth stimulatory activity of growth-regulated gene and the interleukin-8 receptor B in human wound repair. Am. J. Patho.l, 147: 1248-1260, 1995.[Abstract]
  7. Antony V. B., Godbey S. W., Kunkel S. L., Hott J. W., Hartman D. L., Burdick M. D., Strieter R. M. Recruitment of inflammatory cells to the pleural space. J. Immunol., 151: 7216-7223, 1993.[Abstract]
  8. Strieter R. M., Koch A. E., Antony V. B., Fick R. B., Jr., Standiford T. J., Kunkel S. L. The immunopathology of chemotactic cytokines: the role of interleukin-8 and monocyte chemoattractant protein-1. J. Lab. Clin. Med., 123: 183-197, 1994.[Medline]
  9. Peveri P., Walz A., Dewald B., Baggiolini M. A novel neutrophil-activating factor produced by human mononuclear phagocytes. J. Exp. Med., 167: 1547-1559, 1988.[Abstract/Free Full Text]
  10. Paccaud J. P., Schifferli J. A., Baggiolini M. NAP-1/IL-8 induces up-regulation of CR1 receptors in human neutrophil leukocytes. Biochem. Biophys. Res. Commun., 166: 187-192, 1990.[Medline]
  11. Koch A. E., Polverini P. J., Kunkel S. L., Harlow L. A., DiPietro L. A., Elner V. M., Elner S. G., Strieter R. M. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science (Washington DC), 258: 1798-1801, 1992.[Abstract/Free Full Text]
  12. Strieter R. M., Kunkel S. L., Elner V. M., Martonyi C. L., Koch A. E., Polverini P. J., Elner S. G. Interleukin-8: a corneal factor that induces neovascularization. Am. J. Pathol., 141: 1279-1284, 1992.[Abstract]
  13. Strieter R. M., Polverini P. J., Arenberg D. A., Walz A., Opdenakker G., Van Damme J., Kunkel S. L. Role of C-X-C chemokines as regulators of angiogenesis in lung cancer. J. Leukocyte Biol., 57: 752-762, 1995.[Abstract]
  14. Broaddus V. C., Hebert C. A., Vitangcol R. V., Hoeffel J. M., Bernstein M. S., Boylan A. M. Interleukin-8 is a major neutrophil chemotactic factor in pleural liquid of patients with empyema. Am. Rev. Respir. Dis., 146: 825-830, 1992.[Medline]
  15. Boylan A. M., Ruegg C., Kim K. J., Hebert C. A., Hoeffel J. M., Pytela R., Sheppard D., Goldstein I. M., Broaddus V. C. Evidence of a role for mesothelial cell-derived interleukin 8 in the pathogenesis of asbestos-induced pleurisy in rabbits. J. Clin. Invest., 89: 1257-1267, 1992.
  16. Antony V. B., Hott J. W., Kunkel S. L., Godbey S. W., Burdick M. D., Strieter R. M. Pleural mesothelial cell expression of C-C (monocyte chemotactic peptide) and C-X-C (interleukin 8) chemokines. Am. J. Resp. Cell Mol. Biol., 12: 581-588, 1995.[Abstract]
  17. Smith D. R., Polverini P. J., Kunkel S. L., Orringer M. B., Whyte R. I., Burdick M. D., Wilke C. A., Strieter R. M. Inhibition of interleukin 8 attenuates angiogenesis in bronchogenic carcinoma. J. Exp. Med., 179: 1409-1415, 1994.[Abstract/Free Full Text]
  18. Schadendorf D., Moller A., Algermissen B., Worm M., Sticherling M., Czarnetzki B. M. IL-8 produced by human malignant melanoma cells in vitro is an essential autocrine growth factor. J. Immunol., 151: 2667-2675, 1993.[Abstract]
  19. Hu D. E., Hori Y., Fan T. P. Interleukin-8 stimulates angiogenesis in rats. Inflammation, 17: 135-143, 1993.[Medline]
  20. Andrews P. M., Porter K. R. The ultrastructural morphology and possible functional significance of mesothelial microvilli. Anat. Record, 177: 409-426, 1973.[Medline]
  21. Connell N. D., Rheinwald J. G. Regulation of cytoskeleton in mesothelial cells: reversible loss of keratin and increase in vimentin during rapid growth in culture. Cell, 34: 245-253, 1983.[Medline]
  22. Goodman R. B., Wood R. G., Martin T. R., Hanson-Painton O., Kinasewitz G. T. Cytokine stimulated human mesothelial cells produce chemotactic activity for neutrophils including NAP-1/IL-8. J. Immunol., 148: 457-465, 1992.[Abstract]
  23. Lauber B., Leuthold M., Schmitter D., Cano-Santos J., Waibel R., Stahel R. A. An autocrine mitogenic activity produced by a pleural human mesothelioma cell line. Int. J. Cancer, 50: 943-950, 1992.[Medline]
  24. Hott J. W., Sparks J. A., Godbey S. W., Antony V. B. Mesothelial cell response to pleural injury: thrombin-induced proliferation and chemotaxis of rat pleural mesothelial cells. Am. J. Respir. Cell Mol. Biol., 6: 421-425, 1992.
  25. Hayashi S., Kurdowska A., Cohen A. B., Stevens M. D., Fujisawa N., Miller E. J. A synthetic peptide inhibitor for alpha-chemokines inhibits the growth of melanoma cell lines. J. Clin. Invest., 99: 2581-2587, 1997.[Medline]
  26. Richmond A., Thomas H. G. Melanoma growth stimulatory activity: isolation from human melanoma tumors and characterization of tissue distribution. J. Cell. Biochem., 36: 185-198, 1988.[Medline]
  27. Singh R. K., Gutman M., Radinsky R., Bucana C. D., Fidler I. J. Expression of interleukin 8 correlates with the metastatic potential of human melanoma cells in nude mice. Cancer Res., 54: 3242-3247, 1994.[Abstract/Free Full Text]
  28. Norgauer J., Metzner B., Schraufstätter I. Expression and growth-promoting function of the IL-8 receptor b in human melanoma cells. J. Immunol., 156: 1132-1137, 1996.[Abstract]
  29. Arenberg D. A., Kunkel S. L., Polverini P. J., Glass M., Burdick M. D., Strieter R. M. Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice. J. Clin. Invest., 97: 2792-2802, 1996.[Medline]
  30. Lee J., Horuk R., Rice G. C., Bennett G. L., Camerato T., Wood W. I. Characterization of two high affinity human interleukin-8 receptors. J. Biol. Chem., 267: 16283-16287, 1992.[Abstract/Free Full Text]
  31. Harada A., Mukaida N., Matsushima K. Interleukin-8 as a novel target for intervention therapy in acute inflammatory disease. Mol. Med. Today, 2: 482-489, 1996.[Medline]
  32. Folkman J. Tumor angiogenesis. Adv. Cancer Res., 43: 175-203, 1985.[Medline]
  33. Hebert C. A., Baker J. B. Interleukin-8: a review. Cancer Invest., 11: 743-750, 1993.[Medline]



This article has been cited by other articles:


Home page
 Ann. Thorac. Surg.Home page
H. I. Pass, G. J. Brewer, R. Dick, M. Carbone, and S. Merajver
A Phase II Trial of Tetrathiomolybdate After Surgery for Malignant Mesothelioma: Final Results
Ann. Thorac. Surg., August 1, 2008; 86(2): 383 - 390.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
I. H. Benoy, R. Salgado, P. Van Dam, K. Geboers, E. Van Marck, S. Scharpe, P. B. Vermeulen, and L. Y. Dirix
Increased Serum Interleukin-8 in Patients with Early and Metastatic Breast Cancer Correlates with Early Dissemination and Survival
Clin. Cancer Res., November 1, 2004; 10(21): 7157 - 7162.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
A. Catania, G. Colombo, A. Carlin, L. Garofalo, S. Gatti, R. Buffa, N. Carboni, L. Rosso, L. Santambrogio, L. Cantalamessa, et al.
Autocrine inhibitory influences of {alpha}-melanocyte-stimulating hormone in malignant pleural mesothelioma
J. Leukoc. Biol., February 1, 2004; 75(2): 253 - 259.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. M. Mian, C. P. N. Dinney, C. E. Bermejo, P. Sweeney, C. Tellez, X. D. Yang, J. M. Gudas, D. J. McConkey, and M. Bar-Eli
Fully Human Anti-Interleukin 8 Antibody Inhibits Tumor Growth in Orthotopic Bladder Cancer Xenografts via Down-Regulation of Matrix Metalloproteases and Nuclear Factor-{kappa}B
Clin. Cancer Res., August 1, 2003; 9(8): 3167 - 3175.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
S. Huang, L. Mills, B. Mian, C. Tellez, M. McCarty, X.-D. Yang, J. M. Gudas, and M. Bar-Eli
Fully Humanized Neutralizing Antibodies to Interleukin-8 (ABX-IL8) Inhibit Angiogenesis, Tumor Growth, and Metastasis of Human Melanoma
Am. J. Pathol., July 1, 2002; 161(1): 125 - 134.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
B. T. Mossman and D. C. Gruenert
SV40, Growth Factors, and Mesothelioma . Another Piece of the Puzzle
Am. J. Respir. Cell Mol. Biol., February 1, 2002; 26(2): 167 - 170.
[Full Text] [PDF]

Home page
 CarcinogenesisHome page
A. S. Haqqani, J. K. Sandhu, and H.C. Birnboim
Constitutive expression of interleukin-8 by Mutatect cells markedly affects their tumor biology
Carcinogenesis, February 1, 2001; 22(2): 243 - 250.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Q. Shi, J. L. Abbruzzese, S. Huang, I. J. Fidler, Q. Xiong, and K. Xie
Constitutive and Inducible Interleukin 8 Expression by Hypoxia and Acidosis Renders Human Pancreatic Cancer Cells More Tumorigenic and Metastatic
Clin. Cancer Res., November 1, 1999; 5(11): 3711 - 3721.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Galffy, G.
Right arrow Articles by Antony, V. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Galffy, G.
Right arrow Articles by Antony, V. B.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online